Intercept

ICPT NASDAQ
79.52
-2.12
-2.60%
After Hours: 79.64 +0.12 +0.15% 17:56 06/14 EDT
Open
81.29
Prev Close
81.64
High
81.29
Low
78.64
Volume
377.09K
Avg Vol (3M)
820.99K
52 Week High
133.74
52 Week Low
73.01
% Turnover
1.17%
Market Cap
2.57B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Intercept ICPT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
MORE >

Recently

Name
Price
%Change